MedPath

Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS

Recruiting
Conditions
Movement Disorders
Parkinson Disease
Dystonia
Essential Tremor
Registration Number
NCT06553625
Lead Sponsor
Boston Scientific Corporation
Brief Summary

The objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functional neurosurgery.

Detailed Description

The objective of this study is to compile real-world outcomes of Boston Scientific Corporation commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functional neurosurgery.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Study candidate is scheduled to be treated with a commercially approved Boston Scientific RF system for pain or for CNS applications per local Directions for Use (DFU)
  • Signed a valid, IRB/EC/REB-approved informed consent form
Exclusion Criteria
  • Meets any contraindications per locally applicable Directions for Use (DFU)
  • Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or to complete study assessments

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in patient's quality of life (QoL) during the study as compared with baselineUp to 24-Months

Change in quality of life assessments during the study as compared with baseline

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (3)

Uniklinik Köln

🇩🇪

Cologne, Germany

Universitaetsklinikum Dusseldorf

🇩🇪

Dusseldorf, Germany

St. Georges Hospital

🇬🇧

London, United Kingdom

Uniklinik Köln
🇩🇪Cologne, Germany
Boston Scientific Clinical Research
Contact
855-213-9890
BSNClinicalTrials@bsci.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.